Literature DB >> 1730638

Epidermal growth factor (EGF)-stimulated tyrosine phosphorylation and EGF receptor degradation in cells expressing EGF receptors truncated at residue 973.

S J Decker1, C Alexander, T Habib.   

Abstract

Epidermal growth factor (EGF)-stimulated tyrosine phosphorylation of proteins was examined in cells expressing wild-type (WT-EGFR) EGF receptors or EGF receptors truncated at residue 973 (973-EGFR). A much broader spectrum of tyrosine phosphorylated proteins was found following EGF treatment of 973-EGFR expressing cells compared with cells expressing wild-type receptors. Several additional ras GTPase activating protein-associated tyrosine phosphorylated proteins were found in EGF-treated 973-EGFR cells relative to WT-EGFR cells. Additional tyrosine-phosphorylated proteins were also found to co-immunoprecipitate with phospholipase C gamma 1 (PLC gamma 1) following EGF treatment of cells expressing 973-EGFR relative to cells expressing WT-EGFR. EGF-stimulated tyrosine phosphorylation of PLC gamma 1 was found in cells expressing WT-EGFR, but not in cells expressing 973-EGFR. WT-EGF receptor from EGF-treated cells bound well to bacterially expressed src homology (SH) regions of PLC gamma 1 and to a lesser extent to bacterially expressed GTPase activating protein SH regions. No binding of 973-EGF receptor to SH regions of either protein could be detected. EGF treatment greatly reduced the half-life of WT-EGFR, but had relatively little effect on the half-life of 973-EGFR. EGF induced internalization of 973-EGFR at a slower rate than WT-EGFR and caused the appearance of discrete receptor degradation products for both cell types. The data indicate that truncation of the EGF receptor at residue 973 alters receptor substrate specificity, decreases the rate of receptor internalization, and has an inhibitory effect on receptor degradation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1730638

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

Review 1.  Will kinase inhibitors make it as glioblastoma drugs?

Authors:  Ingo K Mellinghoff; Nikolaus Schultz; Paul S Mischel; Timothy F Cloughesy
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

2.  Endocytosis deficiency of epidermal growth factor (EGF) receptor-ErbB2 heterodimers in response to EGF stimulation.

Authors:  Z Wang; L Zhang; T K Yeung; X Chen
Journal:  Mol Biol Cell       Date:  1999-05       Impact factor: 4.138

3.  Direct analysis of the binding of Src-homology 2 domains of phospholipase C to the activated epidermal growth factor receptor.

Authors:  G Zhu; S J Decker; A R Saltiel
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

Review 4.  EGF receptor in neoplasia and metastasis.

Authors:  K Khazaie; V Schirrmacher; R B Lichtner
Journal:  Cancer Metastasis Rev       Date:  1993-09       Impact factor: 9.264

5.  A minor tyrosine phosphorylation site located within the CAIN domain plays a critical role in regulating tissue-specific transformation by erbB kinase.

Authors:  C M Chang; H K Shu; L Ravi; R J Pelley; H Shu; H J Kung
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

6.  Constitutive asymmetric dimerization drives oncogenic activation of epidermal growth factor receptor carboxyl-terminal deletion mutants.

Authors:  Angela K J Park; Joshua M Francis; Woong-Yang Park; Joon-Oh Park; Jeonghee Cho
Journal:  Oncotarget       Date:  2015-04-20

7.  Cell movement elicited by epidermal growth factor receptor requires kinase and autophosphorylation but is separable from mitogenesis.

Authors:  P Chen; K Gupta; A Wells
Journal:  J Cell Biol       Date:  1994-02       Impact factor: 10.539

8.  Structurally related class I and class II receptor protein tyrosine kinases are down-regulated by the same E3 protein coded for by human group C adenoviruses.

Authors:  E Kuivinen; B L Hoffman; P A Hoffman; C R Carlin
Journal:  J Cell Biol       Date:  1993-03       Impact factor: 10.539

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.